Invicta Diagnos. (INVICTA)
Score breakdown: P/E: 2/3 · ROCE: 2/2 · Growth: 0/2 · Dividend: 0/1
Key Financials
| Current Price | ₹78 |
| Market Cap | ₹77.95 Cr |
| P/E Ratio | 16.62 |
| ROCE | 46.45% |
| ROE | —% |
| Dividend Yield | 0% |
| Profit Growth | 0% |
| Debt/Equity | — |
| Sales Growth | 0% |
| Promoter Holding | 66.7% |
| 52-Week Range | ₹58.1 — ₹104.5 |
| Sector | Healthcare Services |
AI Analysis
AI-generated, general educational analysis — not personal investment advice.
At first glance, Invicta Diagnos looks like the kind of small-cap healthcare service provider that can compound quietly. A 46.45% ROCE is genuinely impressive; it suggests management has found ways to earn high returns on capital employed. Promoter holding of 66.70% also aligns owner and outsider interests far better than most listed shells. And at ₹78 with a market cap of only ₹78 Cr, the P/E of 16.62 is not outrageous if those historical earnings are real and repeatable.
The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer